Clinical trials

Disease

Country

Status

Phase

Reset

31,147 trials

2026-525798-38-00
Recruiting
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.
Phase 1 · Romania · 1 site
Registry update: 12 Oct 2026
NCT07416552
Recruiting
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
Phase 1 · United States · 5 sites
Registry update: 3 Nov 2026
2026-525417-31-00
Recruiting
A randomised active-controlled study to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
Phase 2 · Denmark, Norway, Poland, Sweden · 15 sites
Registry update: 29 Sept 2026
NCT07792655
Recruiting
Telerehabilitation for Post-Stroke Hand Function
Not applicable · United States · 1 site
Registry update: 15 Oct 2026
NCT07893106
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight
Phase 1 · United States · 1 site
Registry update: 23 Oct 2026
NCT07909967
Recruiting
Observational Analytical Validation Study of the Replior ScratchSense
Not applicable · France · 1 site
Registry update: 4 Nov 2026
NCT07468695
Recruiting
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 Kenya
Not applicable · Kenya · 1 site
Registry update: 3 Nov 2026
NCT07900438
Recruiting
A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
Phase 4 · China · 26 sites
Registry update: 28 Oct 2026
NCT07574047
Recruiting
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Phase 2 · Switzerland · 9 sites
Registry update: 27 Oct 2026
NCT07822646
Recruiting
A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
Phase 3 · China · 6 sites
Registry update: 16 Sept 2026
NCT07459634
Recruiting
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Phase 2 · United States · 6 sites
Registry update: 6 Nov 2026
NCT07904182
Recruiting
Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
Not applicable · China · 1 site
Registry update: 29 Oct 2026
2026-525932-40-00
Recruiting
An Open-Label, Controlled, Multiple-Dose Phase I Clinical Trial Evaluating the Steady-State Pharmacokinetics, Pharmacodynamics and Safety of SHR-3167 in Subjects With Type 2 Diabetes
Phase 1 · Germany · 1 site
Registry update: 18 Sept 2026
NCT07511166
Recruiting
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
Not applicable · China · 1 site
Registry update: 4 Nov 2026
NCT07863141
Recruiting
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
Phase 2 · China · 1 site
Registry update: 7 Oct 2026
NCT07163143
Recruiting
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
Phase 3 · Pakistan, South Africa, Zimbabwe · 4 sites
Registry update: 26 Oct 2026
NCT07884773
Recruiting
Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-Thalassemia
Phase 3 · Pakistan · 1 site
Registry update: 21 Oct 2026
2025-524928-21-00
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
Phase 3 · Austria, Belgium, Czechia, Germany, Denmark, Spain, France, Italy, Netherlands, Norway, Poland, Sweden · 64 sites
Registry update: 25 Sept 2026
NCT07625800
Recruiting
Switch to Ofatumumab and Level of Immunoglobulins
Not applicable · France · 1 site
Registry update: 30 Oct 2026
NCT07840092
Recruiting
Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
Not applicable · China · 1 site
Registry update: 24 Sept 2026

Ordered by registry start date. Freshness and sponsorship never change the order.